Development program

The lead program aims to develop a disease modifying osteoarthritis drug candidate based on our proprietary BMP technology. 

Together with our scientific and industry partners we have selected a lead product candidate in a long lasting formulation with excellent characteristics.

In the second half of 2022 further data will become available. When interested in meeting us and getting acquainted with our ground breaking technology and development program, please contact us.